KEFUROX IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
When do Kefurox In Plastic Container patents expire, and what generic alternatives are available?
Kefurox In Plastic Container is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in KEFUROX IN PLASTIC CONTAINER is cefuroxime sodium. There are sixty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kefurox In Plastic Container
A generic version of KEFUROX IN PLASTIC CONTAINER was approved as cefuroxime sodium by ACS DOBFAR SPA on May 30th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KEFUROX IN PLASTIC CONTAINER?
- What are the global sales for KEFUROX IN PLASTIC CONTAINER?
- What is Average Wholesale Price for KEFUROX IN PLASTIC CONTAINER?
Summary for KEFUROX IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 44 |
| Patent Applications: | 17 |
| DailyMed Link: | KEFUROX IN PLASTIC CONTAINER at DailyMed |
US Patents and Regulatory Information for KEFUROX IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | KEFUROX IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INJECTION | 062590-002 | Jan 10, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | KEFUROX IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INTRAVENOUS | 062590-001 | Jan 10, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
